MNOVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:11):

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States...

Stats
本日の出来高	9 634.00
平均出来高	49 646.00
時価総額	63.76M
EPS	$0 ( 2024-02-15 )
次の収益日	( $-0.0500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.65
ATR14	$0.0140 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Obrien Geoffrey	Buy	84 000	Employee Stock Option (Right to Buy)
2024-01-09	Matsuda Kazuko	Buy	157 500	Employee Stock Option (Right to Buy)
2024-01-09	Iwaki Yuichi	Buy	210 000	Employee Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	18 333	Stock Option (Right to Buy)
2023-08-04	Lemerond Nicole	Buy	0

INSIDER POWER
98.73
Last 93 transactions
Buy: 6 161 551 \| Sell: 1 269 768

MediciNova Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

MediciNova Inc 財務諸表

Annual	2023
収益:	$1.00M
総利益:	$979 705 (97.97 %)
EPS:	$-0.170

FY	2023
収益:	$1.00M
総利益:	$979 705 (97.97 %)
EPS:	$-0.170

FY	2022
収益:	$0
総利益:	$-212 426 (0.00 %)
EPS:	$-0.290

FY	2021
収益:	$4.04M
総利益:	$0.00 (0.00 %)
EPS:	$-0.207

Financial Reports:

No articles found.

MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.